Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 226Lung Neoplasms 78Neoplasms 37Mesothelioma 23Mesothelioma, Malignant 21Neoplasm Metastasis 20Breast Neoplasms 18Adenocarcinoma of Lung 18Head and Neck Neoplasms 13Colorectal Neoplasms 13Ovarian Neoplasms 11Parkinson Disease 4, Autosomal Dominant Lewy Body 10Carcinoma 8Uterine Cervical Neoplasms 6Non-Squamous Non-Small Cell Lung Cancer 6Adenocarcinoma, Bronchiolo-Alveolar 6Adenocarcinoma 6Unspecified Adult Solid Tumor, Protocol Specific 5Stomach Neoplasms 5Squamous Cell Carcinoma of Head and Neck 5Sarcoma 5Meningeal Carcinomatosis 5Brain Neoplasms 5Urinary Bladder Neoplasms 4Small Cell Lung Carcinoma 4Recurrence 4Prostatic Neoplasms 4Pancreatic Neoplasms 4Laryngeal Diseases 4Endometrial Neoplasms 4

Interventions

Fluorouracil 2Docetaxel 2thymoglobulin 1temsirolimus 1sargramostim 1pirarubicin 1pembrolizumab 1pazopanib 1fludarabine phosphate 1fludarabine 1cc-486 1X-Rays 1Whole-Body Irradiation 1Trastuzumab 1Tacrolimus 1Surveys and Questionnaires 1Rituximab 1Radiotherapy 1Proctectomy 1Pemetrexed 1Oxaliplatin 1Mycophenolic Acid 1Monatide (IMS 3015) 1Metformin 1Melphalan 1Leucovorin 1Granulocyte-Macrophage Colony-Stimulating Factor 1Epirubicin 1Drug Therapy 1Diphenhydramine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Pathologic Complete Response × Pemetrexed × Clear all
NCT00343720 2008-03-13

Study of Alimta® (Pemetrexed) Plus VELCADE® (Bortezomib) or Alimta Alone or VELCADE Alone in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Prior Therapy

Millennium Pharmaceuticals, Inc.

Phase 2 Completed
Thoracic

Pathologic Complete Response, Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon ⚡